ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011
Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02046512 (Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health), which is not on this map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-ResistantFrontiers in medicine · 2021Pooled it
- Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.Antimicrobial agents and chemotherapy · 2014Pooled it
- Treatment outcomes of daptomycin- and vancomycin-resistantJAC-antimicrobial resistance · 2026Article
- Genomic surveillance of vancomycin-resistant Enterococcus faecium: a study on Resistome, Plasmidome, and mobilome profiling.Current genetics · 2025Article
- Non-beta-lactam agents for definitive treatment of ampicillin-susceptibleAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Dynamic collateral sensitivity profiles highlight opportunities and challenges for optimizing antibiotic treatments.PLoS biology · 2025Article
- Vancomycin resistance and virulence genes evaluation inHeliyon · 2024Article
- Synthesis, molecular docking and antibacterial activity of an oxadiazole-based lipoteichoic acid inhibitor and its metabolites.Journal of molecular structure · 2023Article
- Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2022Article
- Daptomycin-ResistantOpen forum infectious diseases · 2022Article
- Article
- Genomic Insights Into Last-Line Antimicrobial Resistance in Multidrug-ResistantFrontiers in microbiology · 2021Review
- Daptomycin Resistance Occurs Predominantly inFrontiers in microbiology · 2021Article
- Daptomycin treatment impacts resistance in off-target populations of vancomycin-resistant Enterococcus faecium.PLoS biology · 2020Article
- Occurrence, Antimicrobial Resistance and Molecular Diversity ofFoods (Basel, Switzerland) · 2020Article
- Establishing the Structure-Activity Relationship of Daptomycin.ACS medicinal chemistry letters · 2020Article
- Article
- Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance.PLoS biology · 2019Article
- Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Daptomycin is the only antibiotic with in vitro bactericidal activity against vancomycin-resistant Enterococcus (VRE) that is approved by the Food and Drug Administration (FDA). Data on the potential emergence of daptomycin nonsusceptibility among enterococci remain limited. We systematically reviewed the published literature for reports of isolates of enterococci that were daptomycin nonsusceptible and assessed the clinical significance and outcome of therapy. Based on susceptibility breakpoints approved by the Clinical Laboratory Standards Institute (CLSI), daptomycin has in vitro activity against >90% of enterococcal isolates. Less than 2% of enterococcal isolates were daptomycin nonsusceptible, with minimum inhibitory concentrations (MICs) >4 μg/mL. The prevalence of nonsusceptibility of VRE isolates to daptomycin may be overestimated due to the spread of clonally related isolates in health care settings. Clinicians should be aware of the possibility of the emergence of daptomycin nonsusceptibility and should closely monitor daptomycin MICs of enterococci isolated during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.